Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kura · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kura Oncology, Inc. (KURA) measures how much investors pay for each dollar of the company's trailing earnings. KURA's current PE ratio of N/A is calculated by dividing its stock price of $8.57 by its TTM earnings per share of -$3.32.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kura Oncology, Inc.You KURA | $761M | N/A | — | -$3.32 |
 Bicara Therapeutics Inc. Common Stock BCAX | $1.1B | N/A | — | -$2.52 |
 EyePoint Pharmaceuticals, Inc. EYPT | $971M | N/A | — | -$3.17 |
 Maravai LifeSciences Holdings, Inc. MRVI | $1.4B | N/A | — | -$0.90 |
 Prime Medicine, Inc. PRME | $540M | N/A | — | -$1.35 |
 ProKidney Corp. PROK | $590M | N/A | — | -$0.52 |
 Replimune Group, Inc. REPL | $741M | N/A | — | -$3.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.18 | — | |
2024-12-31 FY2024 | — | $-2.02 | — | |
2023-12-31 FY2023 | — | $-2.08 | — | |
2022-12-31 FY2022 | — | $-2.03 | — | |
2021-12-31 FY2021 | — | $-1.97 | — | |
2020-12-31 FY2020 | — | $-1.69 | — | |
2019-12-31 FY2019 | — | $-1.51 | — | |
2018-12-31 FY2018 | — | $-1.72 | — | |
2017-12-31 FY2017 | — | $-1.52 | — | |
2016-12-31 FY2016 | — | $-1.47 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kura Oncology, Inc. (KURA) measures how much investors pay for each dollar of the company's trailing earnings. KURA's current PE ratio of N/A is calculated by dividing its stock price of $8.57 by its TTM earnings per share of -$3.32.
Frequently asked questions
KURA pe ratio · 6 questionsKURA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.57 and TTM EPS of -$3.32. Data sourced from Financial Modeling Prep via KURA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kura Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08